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Neutralization of flaviviruses by antibody is primarily mediated via epitopes in the viral envelope (E) protein. Comparative studies using
neutralizing monoclonal antibodies revealed differential expression of epitopes within the E protein domain III of ten naturally occurring
West Nile virus strains representing major subtypes of genetic lineages 1 and 2. Residues that defined these subtype-specific determinants
were identified by mutational studies and found to be surface exposed in the domain III structure. Mutations of residue 332 had the most
significant effects on variation of domain III neutralizing epitopes among strains.
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West Nile virus (WNV) is a member of the Japanese
encephalitis serocomplex of the family Flaviviridae, genus
Flavivirus. Molecular phylogenetic analyses have identified
two major WNV lineages, designated 1 and 2 (Lanciotti et
al., 1999; Scherret et al., 2002), which included genetic
subgroups that correlated well with antigenic subtypes that
had been defined by cross-neutralization studies using
polyclonal sera and monoclonal antibodies (MAbs) (re-
viewed by Scherret et al., 2002). The flavivirus envelope (E)
protein is the major virion surface protein and an important
target for virus neutralizing antibodies. Epitope mapping
studies with several flaviviruses have identified three major
antigenic domains (designated A, B, and C) that correspond
to distinct structural subunits of E (designated structural
domains II, III, and I, respectively) (Rey et al., 1995).
Many antibodies that bind to antigenic domain B/
structural domain III, which is the putative receptor binding0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: d.beasley@utmb.edu (D.W.C. Beasley).domain, are very efficient at neutralizing the infectivity of
flaviviruses and also tend to be virus type or sub-type
specific (reviewed by Roehrig, 2003). Therefore, epitopes
located on domain III of WNV are likely to be highly
significant in the development of protective immunity and
have also been shown to be important in the specific
serological diagnosis of WNV infection (Beasley et al.,
2004b).
Previously, we used commercially available neutralizing
MAbs to select neutralization-resistant variants of a genetic
lineage 1 North American WNV strain, 385-99 (USA99b),
that encoded mutations at surface-exposed residues located
in domain III (K307R or T330I; Beasley and Barrett, 2002).
In addition, a lineage 2 WNV strain that encoded three
amino acid differences within domain III compared to
USA99b was not neutralized by MAbs, suggesting that
significant antigenic differences between WNV strains are
encoded within domain III.
In order to assess the extent of antigenic variation within
domain III among naturally-occurring strains of WNV, and
possibly to identify amino acid residues that define major
antigenic subtypes of WNV, we analyzed ten strains (Table
1) representing genetic lineages 1 and 2 using three005) 99–105
Table 1
Neutralization and Western blot reactivity of West Nile virus strains representative of genetic lineages 1 and 2 with E protein domain III-specific monoclonal
antibodies, a polyclonal rabbit antiserum raised against recombinant WNV USA99b E protein domain III, and a polyclonal mouse antiserum raised against a
New York 1999 isolate
MAb/serum Neutralization indexa (and Western blot reactivity b) against WNV strains
(Epitope)
Lineage 1 Lineage 2
USA99b ETH76a ISR52 ISR53 AUS60 IND80 MAD78 SA89 MAD88 SA58a
5H10 (B1) 2.3 (++) 2.7 (++) 2.2 (++) 0.9 () 1.1 (++) 2.8 (++) 2.5 (++) 1.3 (++) 0.2 () 0.2 ()
5C5 (B2) 2.5 (++) 2.4 (++) 2.4 (++) 1.9 (+/) 1.1 (++) 2.9 (++) 2.5 (++) 1.2 (++) 0.2 () 0.1 ()
7H2 (B3) 3.6 (++) 4.2 (++) 3.4 (++) 2.1 (+/) 1.6 (++) 3.6 (++) 3.1 (++) 1.7 (++) 0.1 () 0.1 ()
Anti-WNV
domain III
3.8 (++) 3.9 (++) 3.9 (++) 3.9 (++) 2.0 (++) z5.6 (++) z4.8 (++) 2.7 (++) 0.3 (++) 0.6 (++)
Anti-WNV 5.1 (++) 5.0 (++) z5.3 (++) 4.1 (+) z4.9 (++) n.d.c (++) n.d. (++) z4.8 (++) n.d. (++) z4.9 (++)
a Neutralization index is log10 reduction in virus titer in the presence of MAb/polyclonal serum compared with culture medium only control.
b Values in brackets represent binding of MAb or antiserum to E protein of eachWNV strain detected in a non-reducing SDS–PAGEWestern blot using Lumigen
chemiluminescent substrate (Amersham Biosciences): b++Q = binding comparable to that observed with strain USA99b; b+Q = reduced binding; b+/Q = binding
detected only after N5 min exposure; bQ = no binding detected.
c n.d., not determined.
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5H10, 5C5, and 7H2 (Bioreliance Corp.)–and a polyclonal
rabbit serum raised against a bacterially-expressed recombi-
nant WNV E protein domain III derived from strain
USA99b (Beasley et al., 2004b). The three MAbs were
raised against the North American prototype strain 382-99
and recognized related but distinct epitopes within domain
III (Beasley and Barrett, 2002) that are designated here as
epitopes B1, B2, and B3, respectively. Details of the ten
WNV strains and their molecular phylogenetic relationships
have been described elsewhere (Beasley et al., 2002,
2004a).Results and discussion
Variable expression of neutralizing epitopes in domain B/III
of WNV strains
The expression of epitopes B1, B2, and B3 among wild-
type WNV strains was assessed by neutralization assay as
well as Western blotting against virus-infected Vero cell
lysate antigens using previously published techniques
(Beasley and Barrett, 2002; Beasley et al., 2004b). Results
of neutralization assays were expressed as bneutralization
indicesQ which represent the log10 reduction in virus titer in
the presence of the MAb or polyclonal antiserum. Although
differences in neutralization by and/or blot reactivity with
the three MAbs did not delineate strains of genetic lineages
1 and 2, variable reactivity with the WNV strains was
observed (Table 1).
Most lineage 1 strains were strongly neutralized by all
three MAbs (neutralization indices 2.3–4.2) and strong
reactivity with their E proteins was detected in Western
blots. Two lineage 2 strains, SA58a and MAD88, were not
significantly neutralized by any of the MAbs (neutralization
indices b1.0), and no reaction with the E proteins of these
strains was detected in Western blots, suggesting thatneutralization escape was mediated via loss of the B1, B2,
and B3 epitopes. Neutralization indices against strains
AUS60 and ISR53 (both lineage 1), and strain SA89
(lineage 2), were 10- to 100-fold lower than against
USA99b. However, all three MAbs reacted strongly with
the E proteins of SA89 and AUS60 in Western blots.
Binding to ISR53 E was also detected, although it was
markedly reduced compared to USA99b and other lineage 1
strains (Table 1).
The anti-domain III rabbit serum reacted strongly with all
E proteins in Western blot assays, but differences in
neutralization of the ten WNV strains were observed (Table
1). Similar to results obtained with the MAbs, strains SA58a
and MAD88 were not neutralized by the anti-domain III
serum, and neutralization of ISR53 and AUS60 was also
reduced compared to USA99b and the other strains. These
results suggested that the mutation(s) associated with escape
from MAb-mediated neutralization for strains SA58a and
MAD88 significantly altered all of the epitopes recognized
by neutralizing antibodies in the polyclonal anti-domain
III serum. Seven of the strains were also compared in
neutralization assays using a polyclonal mouse immune
ascitic fluid (MIAF) raised against strain USA99b (gen-
erously provided from the World Reference Center for
Emerging Viruses and Arboviruses [WRCEVA] by Dr. Bob
Tesh). All seven strains were strongly neutralized by this
MIAF (Table 1), indicating that the E proteins of these
WNV strains have other cross-reactive neutralizing epito-
pe(s), presumably located within the other antigenic/
structural domains.
Identification of domain III amino acids that contribute to
antigenic variation between WNV strains
The domain III coding region of the E gene for each
strain was RT-PCR amplified and sequenced, and the
derived amino acid sequences were compared (Fig. 1). A
maximum of four amino acid differences from strain
Fig. 1. Alignment of domain III amino acid sequences for ten West Nile virus strains used in this study and representative Japanese encephalitis, St. Louis
encephalitis, and Murray Valley encephalitis virus strains (derived from GenBank files U21057, M16614, and M24220, respectively). Conserved residues are
indicated by a dot (bd Q). Residues that were associated with escape from neutralization by monoclonal antibodies are in bold.
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was lineage 2 strain MAD78, which did not differ
appreciably from USA99b in neutralization or Western blot
assays (Table 1).
Disregarding mutations that were shared with strongly
neutralized strains (e.g., A369S in MAD78, MAD88,
SA89, and SA58a), complete or partial escape from
neutralization was associated with the following changes:
L312A and/or T332K for strains SA89, MAD88, and
SA58a; T332A for strain ISR53; K310T and/or A365S for
strain AUS60 (Fig. 1). Each of these residues lies on the
upper surface of WNV domain III, while the other variable
residues were primarily located internal to the domain or on
surfaces that would most likely be hidden in the native
virion (Fig. 2).
To determine which mutation(s) had the greatest effect
on epitopes B1, B2, and B3, domain III MBP fusion protein
constructs encoding candidate mutations individually or in
combination were generated either by RT-PCR amplifica-
tion and cloning of the domain III coding region from viral
RNA or by site-specific mutagenesis of a USA99b domain
III expression plasmid (Beasley et al., 2004b). Fusion
proteins were purified on amylose resin and MAb binding
to each protein was assessed using an indirect ELISA
protocol (Beasley et al., 2004b). Wells of plates were coated
with equal quantities of the fusion proteins (~30 ng/well)
and the MAbs were each diluted to a concentration
approximately 100-fold greater than their Kd (Volk et al.,
2004).Consistent with data from Western blots with virus-
derived antigens, no binding of any MAb was detected to
domain III derived from strain SA58a (mutations L312A,
T332K, A369S) or to a domain III encoding only the T332K
mutation, indicating that the loss of epitopes B1, B2, and B3
in SA58a and MAD88 could be primarily attributed to this
single mutation (Fig. 3; absorbance values not significantly
different to background binding). A T332A mutation (as
occurs in strain ISR53) also reduced MAb binding to all
three epitopes but, consistent with the results of PRNT and
Western blot assays (Table 1), had the greatest effect on
epitope B1. A reduction in MAb binding to each epitope
was also observed as a result of the L312A mutation, which
was consistent with the incomplete neutralization of strain
SA89. However, some neutralization-resistant plaques of
SA89 (picked in the presence of MAb 7H2) encoded the
T332K mutation seen in SA58a and MAD88, indicating that
this mutation was present within the SA89 quasispecies and
most probably contributed to the incomplete neutralization
of this strain by the MAbs (data not shown).
In contrast, mutations K310T and/or A365S, as found in
strain AUS60, did not reduce MAb binding to any epitope.
Rather, binding of each MAb was actually increased
compared to the USA99b control (Fig. 2). Escape from
neutralization due to a mutation in domain III without loss
or reduction in antibody binding has also been reported for a
variant of tick-borne encephalitis virus (Holzmann et al.,
1997). Alternatively, low frequency mutations within the
AUS60 quasispecies that were not detected by consensus
Fig. 2. (a) Locations of residues that differed betweenWest Nile virus strains
in a NMR structure of the West Nile virus E protein domain III (PDB file
1S6N; Volk et al., 2004). Side-on and overhead views of domain III are
oriented as for the complete E ribbon diagrams shown above the domain III
structures. Space-filled residues are those that were associated with
neutralization escape (red color) or that varied betweenWNV strains without
affecting neutralization by monoclonal antibodies (cream color). (b) Surface-
shaded representation of structures shown in panel a highlighting the exposed
locations of residues 310, 312, 332, and 365. Ribbon diagrams were rendered
using Pymol v. 0.97 (Delano Scientific LLC, San Carlos, CA).
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have played a role in the altered neutralization of AUS60
virions by the MAbs.Fig. 3. Presentation of epitopes B1, B2, and B3 on recombinant domain III
MBP fusion proteins incorporating mutations associated with escape from
neutralization. Effects of specific mutations on these epitopes were
determined by reactivity with virus-neutralizing monoclonal antibodies in
an indirect ELISA. An anti-MBP serum (New England Biolabs, Beverly,
MA) was also used as a control to demonstrate that equivalent quantities of
each protein were coated in the wells of ELISA plate.Conclusions
Amino acid mutations in domain III of the WNV E
protein that were associated with antigenic differences
between strains were located at the edges of the solvent-
exposed upper surface of the domain (Fig. 2), and were
primarily non-conservative in nature. Mutations that were
not associated with antigenic differences were generally less
surface exposed and/or more conservative. Overall, the data
reported here suggest that the biochemical nature of amino
acid substitutions as well as their precise location within
domain B/III contributes to the degree of antigenic variation
between WNV strains. In particular, residue 332 appeared to
function as a major antigenic determinant, with differentamino acid substitutions at this site (i.e., T in USA99b, K, or
A in neutralization-resistant strains) having varying effects
on the integrity of epitopes B1, B2, and B3 (Table 1; Fig. 3).
The complete loss of all three neutralizing epitopes was
mediated solely by the T332K mutation, whereas other
mutations (e.g., T332A, L312A) had more subtle effects on
the presentation of these epitopes. Strains MAD88 and
SA58a, which encoded the T332K and L312A mutations,
were not neutralized by MAbs or the anti-WNV domain III
rabbit serum. This suggests that these substitutions were
sufficient to disrupt all of the epitopes recognized by neu-
tralizing antibodies raised against domain III of New York
1999 lineage 1 WNV.
The observation that antigenic differences in domain III
did not clearly discriminate between the major subtypes of
WNV was significant, but is consistent with earlier com-
parisons of WNV strains in which certain MAbs recognized
some but not all of the lineage 1 and 2 strains that were
compared (Besselaar and Blackburn, 1988; Burt et al., 2002;
Morvan et al., 1990; Scherret et al., 2001). Signature E
protein amino acids that discriminated between lineage 1
and 2 WNV strains have been identified, but these were not
located within domain III (Scherret et al., 2001). We
hypothesize that the proposed function of domain III as a
receptor-binding determinant places strong constraints on
the degree to which residues in this domain can vary and
that, as a result, immune pressures can select for only a
limited range of surface variations that maintain virus fitness
and E protein function. However, the observation that
mutation of a single amino acid within domain III can have
such dramatic effects on important neutralizing epitopes
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for serological diagnostic assays that rely on type/subtype
specific, domain III-reactive MAbs and/or subunit E protein
antigens (e.g., Beasley et al., 2004b; Blitvich et al., 2003).
Model domain III structures incorporating the L312A,
T332A/K, K310T, and A365S mutations were generated
from the Swiss-Model structure prediction server (Schwede
et al., 2003; accessed at bwww.expasy.chQ) using a WNV
strain USA99b domain III structure previously determined
by our lab and other collaborators at UTMB as a template
(PDB accession 1S6N; Volk et al., 2004). None of these
models revealed any changes to the predicted folding of
WNV domain III (data not shown), suggesting that the
observed effects on epitopes B1, B2, and B3 were probably
mediated directly via biochemical changes at the domain III
surface caused by mutation of those residues.
In a series of reports, Roehrig and others have described
a comparable type-specific bcritical neutralizing epitopeQ,
designated E1C, in the E proteins of SLEV and MVEV
(Hawkes et al., 1988; Mathews and Roehrig, 1984; Roehrig
et al., 1983; Vorndam et al., 1993). Although those studies
did not identify the specific location of the epitope, the
strong neutralizing activity and high degree of specificity of
the MAbs that recognized E1C in SLEV or MVEV suggest
that it is probably equivalent to WNV epitope B3,
recognized by MAb 7H2, which was disrupted by a
T332K mutation and significantly affected by a T332A
mutation. Residue 332 is located in close proximity to
residues 330 and 307 which were previously associated with
neutralization escape variants of USA99b selected with
MAbs 5H10 and 5C5, respectively (Beasley and Barrett,
2002). However, unlike the T332K mutation, neither a
T330I or K307R mutation prevented binding of MAb 7H2
to domain III (Volk et al., 2004). Mutations of the
corresponding residue of Japanese encephalitis virus (JEV)
domain III had similar effects on the binding of a JEV-
specific neutralizing MAb (Lin and Wu, 2003; Wu et al.,
1997). The apparent importance of residue T332 as a critical
antigenic determinant for WNV suggests that this
uncharged, polar residue may participate directly in anti-
body binding interactions at the surface of domain III,
although this remains to be confirmed experimentally by
structural analysis.Materials and methods
Virus strains, monoclonal antibodies, and antisera
Ten WNV strains representative of major subtypes of
genetic lineages 1 and 2 (listed in Table 1) were obtained
from WRCEVA at UTMB. The propagation and nucleotide
sequencing characterization of the ten WNV strains have
been described elsewhere (Beasley et al., 2002, 2004a). All
working stocks of virus were grown and plaque titrated in
Vero cells.MAbs 5H10, 5C5, and 7H2 were obtained from
Bioreliance Corporation (Rockville, MD) and their proper-
ties and the results of preliminary epitope mapping studies
have been described elsewhere (Beasley and Barrett, 2002).
Rabbit antiserum against the purified, recombinant WNV
domain III protein was prepared by Harlan Bioproducts for
Science (Indianapolis, IN) as described elsewhere (Beasley
et al., 2004b). Polyclonal anti-WNV strain USA99b mouse
serum was obtained from WRCEVA.
Neutralization assays
Ten-fold dilutions of virus were prepared in MEM
tissue culture medium (Sigma, St. Louis, MO) containing
2% fetal bovine serum (FBS) and mixed with equal
volumes of anti-WNV MAb (diluted 1:200), or polyclonal
anti-WNV E-III rabbit serum (1:20), or anti-WNV MIAF
(1:20), or MEM media only. Virus–antibody mixtures
were incubated at room temperature for 60 min before
inoculation onto monolayers of Vero cells in 6-well tissue
culture plates (Nunc). Plates were incubated at room
temperature for 30 min to allow virus adsorption, then
overlayed with 5 mL per well of MEM medium
containing 1% agarose (MEM/agarose). After incubation
at 37 8C in a 5% CO2 atmosphere for 2 days, the wells
were overlayed with an additional 2 mL of MEM/agarose
containing 2% v/v neutral red solution (Sigma). Plaques
were counted the following day and neutralization indices
determined as the log10 reduction in virus titer in the
presence of either MAb, or polyclonal anti-WNV E-III
rabbit serum or anti-WNV MIAF compared with the
medium only control.
Nucleotide sequencing
RNA was extracted from WNV-infected Vero cell super-
natants using the QiaAmp viral RNA extraction kit (Qiagen
Inc., Valencia, CA) and reverse transcribed using AMV
reverse transcriptase (Roche, Indianapolis, IN). A fragment
that included the E-III coding sequence was RT-PCR
amplified using primers WN1751 (5V-1751TGCATCAAGCTQ
TTGGCTGGA1770) and WN2504A (5V-2504TCTTGCCGGQ
CTGATGTCTAT2485) for lineage 1 strains, or WN1739
(5 V- 1751TGCACCAAGCTCTGGCCGGA1770) and
WN2498A (5V-2510CGGAGCTCTTGCCTGCCAAT2491)
for lineage 2 strains. Primer pairs were designed based
on GenBank sequences AF196835 and M12294, respec-
tively, and are numbered according to residues in the
AF196835 sequence. PCR products of the appropriate sizes
were gel purified and directly sequenced using the ABI
PRISM Big Dye v3.0 cycle sequencing kit (Applied
Biosystems, Foster City, CA) on an ABI PRISM 3100
genetic analyzer (Applied Biosystems) according to the
manufacturer’s protocols. Sequence analyses were per-
formed using the Vector NTI Suite package (Informax
Inc., Bethesda, MD).
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Site-directed mutagenesis of the WNV strain USA99b
domain III gene fragment cloned in the MBP fusion protein
expression vector pMAL-c2x (New England Biolabs
[NEB], Beverley, MA; Beasley et al., 2004b) was performed
using the Quikchange kit (Stratagene, La Jolla, CA)
according to the manufacturer’s instructions. In addition,
the domain III coding regions from strains ISR53 and
SA58a were RT-PCR amplified and cloned into pMAL-c2x
in DH5a E. coli as described previously (Beasley et al.,
2004b).
For each protein, a 20-mL culture of bacteria in LB
medium containing ampicillin was grown to an OD600 ~0.6
and then induced with 1 mM ITPG at 37 8C for 120 min.
Bacterial cells were pelleted by centrifugation and stored
overnight at 20 8C before being lysed in 1 mL of MBP
column buffer (20 mM Tris–HCl, 200 mM NaCl, 1 mM
EDTA) by freeze–thaw using liquid nitrogen. Fusion
proteins were purified from these whole cell lysates using
a protocol similar to that recommended by the manufacturer
(NEB). Briefly, the lysates were microfuged (12,000 rpm/
4 8C/30 min) and the clarified supernatants were then mixed
with a small quantity of amylose resin (NEB) in a 1.5 mL
eppendorf tube and incubated on ice for 15 min. The tubes
were microfuged at low speed (3000 rpm/60 s) and the
supernatant removed. The resin was washed twice with 1 mL
of native lysis buffer and the bound protein was then eluted
in four washes of 0.25 mL of MBP column buffer
containing 10 mM maltose. Concentrations of the purified
proteins were determined by commercial Bradford assay
(Sigma) according to the manufacturer’s protocol and by
spectrophotometric analysis.
Indirect ELISA
Binding of MAbs to purified MBP domain III fusion
proteins was assessed using an indirect ELISA protocol as
described elsewhere (Beasley et al., 2004b). Briefly, wells of
96-well ELISA plates (Corning Inc., Corning, NY) were
coated overnight with 30 ng of purified proteins diluted in
borate saline (pH 9.0). Coated plates were blocked for 60
min at room temperature with a solution of phosphate-
buffered saline (PBS) containing 3% bovine serum albumin
(BSA). As outlined in the Results above, MAbs were
diluted in PBS containing 0.5% Tween 20 (PBS/Tween) to a
concentration of 10–20 nM, which was approximately 100-
fold greater than their Kd values (Volk et al., 2004). To
confirm that equivalent quantities of each fusion protein had
been coated in the wells of ELISA plates, an anti-MBP
serum (NEB) diluted according to the manufacturer’s
recommendations was included in each assay as a control.
ELISA reactions were performed in triplicate wells for each
MAb–protein combination. Plates were incubated at room
temperature for 45 min, washed three times with PBS/
Tween, and peroxidase-labeled anti-mouse IgG antibody(Sigma) diluted in PBS/Tween was added to each well.
After a further 45-min incubation, plates were again washed
and reactions visualized by addition of 3,3V,5,5V-tetrame-
thylbenzidene substrate (Sigma). After 10 min, reactions
were stopped by addition of 3 M HCl and the absorbance
values read on a model 3550-UV plate reader (Bio-Rad,
Hercules, CA) at 450 nm with a reference of 595 nm.Acknowledgments
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